OncOlOgy & HeMatOlOgy Review muscle may be difficult and sometimes impossible to deal with surgically (see Figure 1 ).
Preoperative Quantitative Prognostic Indicators
Preoperatively, diagnostic tests can be used to select patients who are likely to benefit from the prolonged surgery combined with hyperthermic perioperative chemotherapy (HIPEC). Cerruto and colleagues have shown the prognostic significance of histomorphologic parameters in assessing prognosis. 4 They quantitated the nuclear and nucleolar size and
showed that it had a profound impact on outcome when patients had a With nuclear/nucleolar size 2, the nuclei remain moderately uniform in size, measuring between 21 and 30 µm. The chromatin pattern is granular and diffuse. The nucleoli are conspicuous and measure less than 3 µm (see Figure 3 ).
With nuclear/nucleolar size 3, the cells exhibit large and irregular nuclei measuring 31-40 µm. There is eccentric clearing of the chromatin. The nucleoli are prominent, measuring 3-5 µm (see Figure 4 ).
With nuclear/nucleolar size 4, the nuclei measure greater than 40 µm.
They are similar in size to lymphocytes or macrophages seen in the Abdominal wall hernia (10 %)
Guarding and rebound tenderness (10 %)
Pleural effusion (5 %) field. There is eccentric clearing of the chromatin. There is a presence of macronuclei greater than 6 µm (see Figure 5 ).
When the survival of 62 patients treated in a uniform manner with cytoreductive surgery, HIPEC and EPIC paclitaxel were reviewed, there were clear survival differences when patients were placed in prognostic groups 1-4 based on nuclear/nucleolar size. There were no treatment failures with nuclear/nucleolar size 1 patients. Five-year survival was 50 % in those with nuclear/nucleolar size 2 and significantly less in nuclear/nucleolar sizes 3 and 4. These data are shown in Figure 6 . It is clear that careful study of a biopsy from the peritoneal mesothelioma is extremely important in the preoperative assessment of prognosis in these patients.
Preoperative Prognostic Assessment using Computed Tomography
Yan and colleagues performed an analysis of the preoperative CT scans of 30 patients with peritoneal mesothelioma who were then treated in a standardized fashion using cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single institution. 5 These patients were divided into two groups depending on the extent of disease that remained after the cytoreduction. Those with residual lesion less than or equal to 2.5 mm were placed in the adequate cytoreduction group. Those with lesions greater than 2.5 mm remaining after maximal surgical efforts were placed in a suboptimal cytoreduction group. The preoperative CT scans for each patient were evaluated by a standardized scoring system.
Thirty-nine CT parameters were obtained and statistically analyzed to determine their association with the adequacy of the cytoreductive surgery. Following the radiologic assessments, the statisticians were asked to construct a tree-structured diagram to allow the preoperative assessment of adequate cytoreduction. All the different combinations of the CT parameters were statistically tested for their predictive value.
The two concerning radiologic features that combined most effectively to identify patients who would have suboptimal cytoreduction were tumor size greater than 5 cm in the epigastric region and class 3 changes within the small bowel and small bowel mesentery (see Figure 7) . If a tumor in the epigastric region was less than 5 cm and there were no class 3 small bowel and small bowel mesentery change, 94 % of patients had an 
Cells exhibit large nuclei (31-40 μm). There is eccentric clearing of the chromatin. The nucleoli are prominent (3-5 μm) (hematoxylin-eosin, original magnification x40, objective).
OncOlOgy & HeMatOlOgy Review optimal cytoreduction. By contrast, if tumor size in the epigastric region was greater than 5 cm and there were class 3 small bowel and small bowel mesentery findings, 100 % of patients had a suboptimal cytoreduction.
The interpretative CT classification of small bowel and its mesentery is an important parameter in preoperative evaluation. Table 2 Yan and colleagues showed that CT can effectively identify the presence of peritoneal mesothelioma at crucial anatomic sites and create a list of concerning radiologic features that suggest suboptimal cytoreductive surgery. As will be seen below, this is extremely important because adequate cytoreduction is necessary to achieve a prolonged survival with the combined treatment. Preoperative CT scans are an accurate prognostic radiologic test for patient selection for a comprehensive treatment plan.
Intraoperative Assessment of Prognosis
As the surgeon explores the abdomen of a patient with DMPM, a careful assessment of the distribution and extent of disease must occur. This is quantitatively recorded on a diagram referred to as the peritoneal cancer index (PCI) (see The PCI has been determined to be a useful prognostic indicator in DMPM patients. Sugarbaker and colleagues showed that a PCI between 0 and 28 was associated with a median survival of 67 months. 2 A PCI between 29
and 39 showed a 26-month median survival (p=0.046).
Intraoperative Prognostic Assessment by Cytoreduction Score
The second intraoperative quantitative prognostic indicator is the completeness of cytoreduction (CC) score). This is determined after the surgeon's best efforts using peritonectomy procedures and visceral Table 3 .
The treatment plan that has evolved in these patients over the last 2 decades is shown in Figure 10 . The first step in treatment is to establish a diagnosis. With the biopsy, the prognostic significance of histomorphologic The standardized orders for long-term intraperitoneal chemotherapy through an intraperitoneal port are shown in Table 6 .
This index combines a size and a distribution parameter to achieve a numerical score. The lesion size (LS) is used to quantitate the size of peritoneal nodules. LS-0 indicates no tumor seen, LS-1 indicates tumor implants up to 0.5 cm, LS-2 indicates tumor implants between 0.5 and 5 cm, and LS-3 indicates tumor implants larger than 5 cm or a layering of cancer. The distribution of tumor is determined within the 13 abdominopelvic regions. Two transverse planes and two sagittal planes are used to divide the abdomen into nine abdominopelvic regions (AR-0 through AR-8). The upper transverse plane is located at the lowest aspect of the costal margin. The lower transverse plane is placed at the anterior superior iliac spine. The sagittal planes divide the abdomen into three equal sectors. These lines define nine regions that are numbered in a clockwise direction with 0 at the umbilicus and 1 defining the space beneath the right hemidiaphragm. The small bowel is assessed as an additional four abdominopelvic regions designated AR-9 through AR-12 and includes the upper jejunum, lower jejunum, upper ileum, and lower ileum, respectively. The summation of the lesion size score in each of the 13 abdominopelvic regions is the peritoneal cancer index (PCI) ranging from 0 to 39.

Results of the Evolution of Treatment Strategies for Peritoneal Mesothelioma Over 2 Decades
The evolution of treatments that has occurred at the Center for
Gastrointestinal Malignancies, MedStar Washington Hospital Center is as follows. In group 1 patients, the treatments were limited to cytoreduction plus HIPEC doxorubicin and cisplatin (n=42). The group 2 patients had cytoreduction plus HIPEC cisplatin and doxorubicin combined with EPIC paclitaxel (n=59). In group 3, the patients had cytoreduction plus HIPEC doxorubicin and cisplatin, EPIC paclitaxel, and combined intraperitoneal pemetrexed and systemic cisplatin for 6 months (n=29). These data clearly show the marked improvement in survival of these patients when the long-term regional chemotherapy treatments were used.
The 10-year survival for group 1 is 24 %, group 2 38 %, and group 3 73 %.
These survival estimates were significant with a p=0.0276. These results need to be interpreted with great caution. It must be clearly stated that patient groups were not compared in the context of controlled trials.
Also, improvements in the learning curve, especially improved patient selection, may have contributed (at least in part) to better prognosis. The study has been carried out over 20 years.
In conclusion, peritoneal dissemination of peritoneal mesothelioma is the only major pathway for spread of this disease. This regional dissemination suggests that advanced treatments within the abdomen and pelvis may be associated with benefit. Patients can now be selected for benefit based on preoperative quantitative prognostic indicators using histomorphologic pathologic parameters and a carefully performed CT scan of the chest, abdomen, and pelvis. Clearly, these two preoperative assessments are of great value in excluding patients who will not profit from the aggressive management plan that does carry a mortality of 1 % and serious morbidity of 12 %. Following the best efforts at cytoreduction, regional chemotherapy treatments using HIPEC (cisplatin, doxorubicin, and ifosfamide) combined with EPIC (paclitaxel) are used. Long-term intraperitoneal or combined intraperitoneal and systemic treatments are associated with a marked improvement in survival suggesting that this long-term treatment should be added to the standard of care for these patients. It is suggested that this long-term local-regional treatment strategy be substituted for systemic chemotherapy in patients with this disease process. n 
